Eigen Therapeutics

Our priming platform extends beyond HER3: we're actively advancing programs including Nectin-4 & CD123, with ongoing screens for PSMA, GRPR, and other key ADC/RLT targets. Stop by and discuss how priming therapies can overcome tumor heterogeneity and reshape oncology treatment!

This poster details our HER3 program: showcasing how we identify molecules that selectively upregulate HER3, aiming to improve treatment durability & expand the patient population for HER3-directed therapies. CTO @Kamran_Allele & CSO Kathryn Vanderlaag will be attending.

📅 Join us at #AACR25 on Sun, Apr 27, 2-5 PM, Section 16, Board 5 (Poster #338) for an in-depth look at how our priming platform expands the patient population & improves efficacy of ADCs and RLTs via selective antigen upregulation to tackle heterogeneity! abstractsonline.com/pp8/#!/20273/p…

This #RareDiseaseWeek, we’re proud to celebrate our friends at @eigenTx + their work revolutionizing #cancertreatments. Their innovative platform is enhancing targeted therapies, offering new hope for rare disease patients. Learn about their work here: hubs.ly/Q038nJh10

This research paves the way for not just increased durability of patient responses, but also broadens the potential patient base benefiting from antigen-directed therapies. Stop by during #AACR2024 to see how we're pushing boundaries and shaping the future of cancer treatment.

Antigens that we’ve utilized our platform on include CD123, HER2, HER3, TROP2, CD33, CD19, and CD22 (with more to come this year!).

📅 Join us at #AACR2024 on April 9, 9:00 AM - 12:30 PM, Poster Section 42, Board #14 (Abstract #5092) for an in-depth look at how our priming platform expands the therapeutic window of antigen-directed therapies (ADCs, RLTs) through antigen modulation! abstractsonline.com/pp8/#!/20272/p…

Eigen's CSO Kathryn, Senior Scientist Anu, and CTO Kamran are at #ASH2022! If you'd like to hear more about priming therapies, reach out to @Kamran_Allele (his DMs are open) or fill out the form at the bottom of eigentx.com.

At Eigen, we’re tackling tumor heterogeneity by utilizing our platform to design combination therapies. Click here to learn more about our mission and team. eigentx.com

A huge thank you to @joshk and the @firstround team, @BuildersVC, @dropalltables, @MDe_Silva, @biovergehq, and many others. Your support and guidance have been key in helping us get here—and we’re just getting started! businesswire.com/news/home/2022…

Targeted therapies are incredibly effective in some instances but can fail in others because cancer is heterogeneous. So we asked ourselves: what if we made cancer cells easier for targeted therapies to eliminate? businesswire.com/news/home/2022…

Today we’re excited to announce our official launch! A big thank you to @KatherineMLewin and the great folks at @endpts for sharing our story. endpts.com/priming-therap…